Metastatic Breast Cancer

In this video, Paolo Tarantino, MD, discusses findings from the EMERALD phase 3 trial presented at San Antonio Breast Cancer Symposium.

In this video, Sara M. Tolaney, MD, MPH, discusses recent findings from DESTINY-Breast03 that assessed the use of fam-trastuzumab deruxtecan-nxki in previously treated patients with HER2-positive unresectable or metastatic breast cancer.

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Longer duration of cyclin-dependent kinase 4/6 inhibitor therapy in the metastatic setting appeared associated with extended PFS among elacestrant-treated patients with advanced breast cancer, according to study results.

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer, according to study findings.

The FDA granted fast track designation to REM-001 for the treatment of cutaneous metastatic breast cancer.

The FDA granted priority review to sacituzumab govitecan-hziy for treatment of certain patients with advanced breast cancer.

The FDA granted priority review to elacestrant for ER-positive, HER2-negative advanced or metastatic breast cancer.

Abemaciclib resulted in an approximately twofold higher venous thromboembolism rate in a real-world setting compared with clinical trials among patients with metastatic breast cancer, according to study results published in Cancer.

The FDA granted fast track designation to several oncology and hematology therapies.